Letybo (Botulinum Toxin Type A)

Botulinum toxin type A cleaves the SNAP‑25 protein, which is essential for the release of acetylcholine at the neuromuscular junction. By preventing acetylcholine release, the toxin blocks nerve‑muscle signaling, leading to a temporary, localized reduction in muscle contraction that can last from weeks to several months.

The dose of Letybo is individualized. The prescribing physician determines the amount, injection sites, and frequency based on the specific indication, patient characteristics, and therapeutic goals. No fixed regimen is provided in the product information.

Safety data for Letybo in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Letybo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Letybo is a botulinum toxin type A formulation comparable to other type A products such as onabotulinumtoxinA and incobotulinumtoxinA. While potency units and clinical trial data may differ, the core mechanism—acetylcholine blockade—is the same. Choice among products often depends on regulatory approval, dosing conventions, and physician experience.

Letybo must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The product should be kept in its original packaging until ready for reconstitution and administration to maintain stability and potency.

Letybo is administered by a trained healthcare professional via intramuscular injection. The injection technique, depth, and volume depend on the targeted muscle group and the therapeutic indication. Proper aseptic technique and accurate dosing are essential for optimal outcomes.

Serious risks include the spread of toxin effect leading to dysphagia, respiratory compromise, generalized muscle weakness, and rare allergic reactions such as anaphylaxis. Patients should be monitored for these signs, especially after the first treatment, and any concerning symptoms should prompt immediate medical evaluation.

Letybo is contraindicated in individuals with a known hypersensitivity to botulinum toxin type A or any excipients in the formulation. Caution is advised for patients with neuromuscular disorders (e.g., myasthenia gravis), those taking certain muscle‑relaxing medications, and pregnant or nursing women unless the benefit justifies the risk.